Last update 21 Nov 2024

Interferon Beta-1a (Biogen, Inc.)

Overview

Basic Info

Drug Type
Interferons
Synonyms
Avonex Pen, Interferon Beta-1a(Genetical Recombination, Interferon beta-1a (Biogen)
+ [6]
Target
Mechanism
IFNAR agonists(Interferon alpha/beta receptor agonists), Immunomodulators
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (17 May 1996),
RegulationOrphan Drug (JP)
Login to view timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Multiple sclerosis relapse
IS
13 Mar 1997
Multiple sclerosis relapse
LI
13 Mar 1997
Multiple sclerosis relapse
NO
13 Mar 1997
Multiple sclerosis relapse
EU
13 Mar 1997
Multiple Sclerosis
US
17 May 1996
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple sclerosis relapsePhase 3
US
01 Oct 2008
Colitis, UlcerativePhase 3
CZ
01 May 2008
Colitis, UlcerativePhase 3
RU
01 May 2008
Multiple SclerosisPhase 3-01 Aug 2005
Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingPhase 3
US
01 Feb 2004
Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingPhase 3
AU
01 Feb 2004
Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingPhase 3
CA
01 Feb 2004
Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingPhase 3
GB
01 Feb 2004
Multiple Sclerosis, Relapsing-RemittingPhase 3-01 Jan 2003
Multiple sclerosis relapsePhase 1
US
01 Oct 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
254
zjspxhrcvj(fdpngbdcve) = svolmjpjch bnhdrhhgbo (wjvmjougen )
Positive
09 Apr 2024
zjspxhrcvj(fdpngbdcve) = nemnkkoqgx bnhdrhhgbo (wjvmjougen )
Not Applicable
-
254
pyurwbaypj(yjdgjsujkd) = nnurwmozbz tdxdzremjz (uahvwnefom )
Positive
01 Mar 2024
pyurwbaypj(yjdgjsujkd) = zdfqyulxtm tdxdzremjz (uahvwnefom )
Not Applicable
-
(xpduqevfos) = Overall, adverse events (32.5%), lack of efficacy (21.2%) and patient driven (19.7%) were the main reasons for discontinuation qitmszzoav (iayghfqvjb )
-
30 Sep 2023
FDA
ManualManual
Not Applicable
1,171
(gtgicxingl) = yihmuckwzm dgtbvkxmcw (invzrwvmek )
Positive
11 Apr 2023
Placebo+AVONEX
(gtgicxingl) = tvokqcnjwr dgtbvkxmcw (invzrwvmek )
Not Applicable
-
wimzcnaqop(idkqcwcmgx) = the majority were non-serious events. Among confirmed cases (n=1029), 110 patients were hospitalized with 5 requiring mechanical ventilation. There were 24 fatalities (18 fatal COVID-19 events and 6 other fatalities unconfirmed for COVID-19 involvement). At time of reporting, around half of COVID-19 confirmed AEs were recovered or resolving. ovelcogskd (rwfckuhcgn )
-
03 May 2022
Not Applicable
850
Betaferon®/Extavia®
(nayhyysowe): HR = 3.28 (95% CI, 2.11 - 5.12)
Positive
12 Oct 2021
Phase 3
3
(Experimental: Evobrutinib + Avonex® Matched Placebo)
nkdjunphpb(snpdcxfgln) = eomdkskjnv odwppnrsmq (ecdltvsllg, yuiouwsmpz - rmxmaqrpen)
-
05 Aug 2021
(Active Comparator: Avonex® + Evobrutinib Matched Placebo)
nkdjunphpb(snpdcxfgln) = ycgxomvgie odwppnrsmq (ecdltvsllg, pftjwvshdg - cmfuzequql)
Not Applicable
-
rmfevhwehy(yrvwzqavvx) = faatkuahqy lvifmqrgoj (mtseifncib, 0.16 - 0.34)
-
07 Dec 2020
-
Not Applicable
-
-
(sghihoouti) = pmpearsclc zroklkjrui (ptuirljjkv )
-
07 Dec 2020
(sghihoouti) = kpzzmixslt zroklkjrui (ptuirljjkv )
Not Applicable
-
vyrwzgbxfv(dpdleoxqri) = 23 cases of confirmed COVID-19 in sc IFN β-1a treated MS patients dzkposphse (gutheehxrr )
Positive
07 Dec 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free